S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:ATBPD

Antibe Therapeutics Stock Forecast, Price & News

$3.68
+0.04 (+1.10 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.44
Now: $3.68
$3.75
50-Day Range
$2.83
MA: $3.72
$5.54
52-Week Range
$2.64
Now: $3.68
$3.50
Volume27,159 shs
Average Volume29,710 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.57
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATBPD
CUSIPN/A
CIKN/A
Phone416 922 3460
Employees47
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.51 million
Book Value$0.10 per share

Profitability

Net Income$-14,540,000.00
Net Margins-273.96%

Miscellaneous

Market Cap$1.42 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.13 out of 5 stars

Medical Sector

1801st out of 1,969 stocks

Pharmaceutical Preparations Industry

730th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$3.68
+0.04 (+1.10 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATBPD News and Ratings via Email

Sign-up to receive the latest news and ratings for ATBPD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antibe Therapeutics (NASDAQ:ATBPD) Frequently Asked Questions

What stocks does MarketBeat like better than Antibe Therapeutics?

Wall Street analysts have given Antibe Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antibe Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 62)
  • Dr. John Lawrence Wallace M.B.A., M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director (Age 63)
  • Mr. Alain Wilson M.B.A., MBA, Chief Financial Officer
  • Dr. David James Vaughan, Chief Devel. Officer (Age 70)
  • Mr. Scott Curtis C.F.A., M.Eng, CFA, Exec. VP
  • Ms. Christina Cameron B.B.A., VP of Investor Relations
  • Mr. Philip Stern, VP of Communications
  • Dr. Rami Batal M.B.A., Ph.D., Chief Commercial Officer
  • Ms. Ella Korets Smith M.B.A., M.Sc., Head of Regional Bus. Devel.
  • Dr. Joseph Stauffer, Chief Medical Officer (Age 54)

Who are some of Antibe Therapeutics' key competitors?

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the NASDAQ under the ticker symbol "ATBPD."

How do I buy shares of Antibe Therapeutics?

Shares of ATBPD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATBPD stock can currently be purchased for approximately $3.68.

How much money does Antibe Therapeutics make?

Antibe Therapeutics has a market capitalization of $1.42 billion and generates $7.51 million in revenue each year. The company earns $-14,540,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Antibe Therapeutics have?

Antibe Therapeutics employs 47 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

Where are Antibe Therapeutics' headquarters?

Antibe Therapeutics is headquartered at 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The company can be reached via phone at 416 922 3460 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.